Using Immune Cells Inside Tumors for Cancer Treatment

Tumor-infiltrating lymphocyte (TIL) therapy has received FDA approval and is expanding into new solid tumor types.

• TIL therapy has shown success in treating melanoma, leading to significant regulatory approval.
• There is a growing interest in applying TIL therapy to other solid cancers beyond melanoma.
• Innovations in TIL design aim to enhance specificity, persistence, safety, and function in therapy.
• Refined manufacturing strategies are being developed to create more potent TIL populations.
• Numerous clinical trials are currently investigating the efficacy of TIL therapy in various solid tumors.

Simplified